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Mitochondrial dynamicsThis overview discusses the results of research on the effects of most frequent mtDNA point mutations on cellular
bioenergetics. Thirteen proteins coded by mtDNA are crucial for oxidative phosphorylation, 11 of them constitute
key components of the respiratory chain complexes I, III and IV and 2 of mitochondrial ATP synthase. Moreover,
pathogenic point mutations in mitochondrial tRNAs and rRNAs generate abnormal synthesis of the mtDNA
coded proteins. Thus, pathogenic point mutations in mtDNA usually disturb the level of key parameter of
the oxidative phosphorylation, i.e. the electric potential on the inner mitochondrial membrane (Δψ), and
in a consequence calcium signalling and mitochondrial dynamics in the cell. Mitochondrial generation of
reactive oxygen species is also modiﬁed in the mutated cells. The results obtained with cultured cells and
describing biochemical consequences of mtDNA point mutations are full of contradictions. Still they help
elucidate the biochemical basis of pathologies and provide a valuable tool for ﬁnding remedies in the future.
This article is part of a Special Issue entitled: 17th European Bioenergetics Conference (EBEC 2012).
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria play a crucial role in the maintenance of cellular ho-
meostasis and participate in numerous cellular processes, for exam-
ple: ATP production, generation of reactive oxygen species (ROS),
generation and transmission of calcium signals and, last but not
least, apoptosis. All these processes depend on and mutually affect
one another, making the functional analysis of mitochondria very
complex. Moreover, mitochondrial proteins are encoded by two ge-
nomes (mitochondrial, mtDNA and nuclear, nDNA).
Mitochondrial genome encodes 13 proteins of the respiratory
chain complexes (complex I — ND1-6 and ND4L, III — cytochrome
b, IV — COX I–III) and ATP synthase (ATPase6 and ATPase8), 2
rRNAs and 22 tRNAs. It is particularly vulnerable to mutations, since
it is in close proximity to ROS generation sites and is not protected
by histones or membranes. Up to now, more than 250 pathogenic
mtDNA mutations have been described [1]. Since there are several
hundred to several thousands of circular mtDNAmolecules in a single
cell, mtDNA mutations are usually heteroplasmic: only a certain pro-
portion of mtDNAs within the cell contains the mutation.
Mutations inmitochondrial genes lead to complex andmultisystemic
disorders known as mitochondrial diseases [2–4]. The age of their onsetopean Bioenergetics Conference
imental Biology, Pasteur St. 3,
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ski).
l rights reserved.is diverse and ranges from infancy to adulthood, and so does the severity
of the symptoms which, in the ﬁrst place, affect tissues with high energy
demand: the central nervous system, cardiac and skeletalmuscles, retina
and the endocrine system. Thus, cardiomyopathy, neurodegenerative
diseases, blindness, cancer or diabetes are often associated with mito-
chondrial dysfunction [1].
Since the samemtDNAmutation canmanifest itself with different
symptoms and severity, the pathophysiological analysis of mito-
chondrial diseases is difﬁcult. Most studies have focused on under-
standing of the variable consequences of mtDNA mutations on the
cellular level using cells obtained from patients, cybrid and Rho0
cells and cells with dysfunction of individual respiratory chain com-
plex or synthase ATP. In this review, we will concentrate on the mi-
tochondrial metabolic consequences of primary mtDNA diseases
which are caused by mtDNA point mutation. Their clinical expres-
sion is wide and includes phenotypes such as: MELAS (Mitochondrial
Encephalopathy, Lactic Acidosis, and Stroke-like episodes), MERRF
(Myoclonic Epilepsy and Ragged Red Fibres), LHON (Leber's Heredi-
tary Optic Neuropathy) and NARP (Neuropathy, Ataxia, and Retinitis
Pigmentosa).
MELAS is the most common mtDNA mutation caused by the point
A3243G mutation in the tRNALeu gene (typical mutation for 80–90%
of patients with MELAS), but other mutations like G1642A in tRNAVal
gene, G3244A, T3258C, T3291C, A3243G and T3271C in tRNALeu gene,
and various other mutations like: A12770G, A13045C, G13513A and
A13514G in ND5 gene as well as in ND1 gene have also been identiﬁed.
Typical for the MELAS syndrome are stroke-like episodes, seizures, de-
mentia, diabetes, ataxia, epilepsy, optic atrophy, deafness, migraine,
cortical blindness, cardiomyopathy, myopathy, exercise intolerance,
lactic acidosis and vomiting.
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by a point mutation A8344G in the tRNALys gene. It usually presents
itself between childhood and early adulthood. The clinical manifesta-
tion of this mutation depends on the percentage of the affected
mtDNA copies and includes myoclonic epilepsy, encephalomyopathy,
ataxia, myopathy, dementia, deafness and others.
The LHON syndrome is mostly caused by three primary muta-
tions: G11778A, G3460A and T14484C in the ND4 genes. Typical fea-
tures of the syndrome are impaired visual acuity and blindness, more
predominant in males.
The NARP syndrome is accompanied by the T8993G or T8993C
mutations in the ATP6 gene and is characterized by ataxia, retinitis
pigmentosa, mental retardation, encephalopathy, developmental
delay, cardiomyopathy, epilepsy, dementia and gastrointestinal disor-
der. Higher than 90% of heteroplasmy cause the Leigh Syndrome
(subacute necrosing encephalomyopathys) a neuropatologically de-
ﬁned multisystem disorder of infancy. Its clinical picture is dominated
by seizures, weakness, hypotonia, developmental delay and lactic
acidosis.
Since mtDNA codes exclusively for proteins of the oxidative sys-
tem its phenotypicaly manifested mutations usually alter the activity
of the oxidative phosphorylation system with typical reduction in
ATP production, enhanced generation of ROS, changes in calcium ho-
meostasis and reorganization of the mitochondrial network. The main
aim of this review is to provide a comprehensive overview of dis-
turbed bioenergetics of the cell corresponding to the most common
mitochondrial diseases caused by mtDNA point mutations.2. Mitochondrial membrane potential and ATP levels in cells with
mtDNA point mutations
The driving force for mitochondrial ATP synthesis is the electro-
chemical proton gradient created by the respiratory chain. Thus,
pathogenic mutations in mtDNA affecting the activity of mitochondri-
al respiratory chain and/or mitochondrial ATP synthase result in de-
creased efﬁciency of mitochondrial ATP synthesis. This was
conﬁrmed by many studies performed on cells with mtDNA muta-
tions, both within the primary cells of patients with mitochondrial
diseases as well as cybrids [5–11]. Impaired mitochondrial ATP syn-
thesis was shown in cells with mutations in genes coding for the re-
spiratory chain complexes [11,12], for tRNAs [6,8] as well as in ATP
synthase [9,10]. Studies on homoplasmic cybrids with different
mtDNA mutations demonstrated a dramatic drop of mitochondrial
ATP synthesis in case of two different MERRF mutations in tRNALys
gene (above 90% decrease in ATP synthesis) and also strong effect of
two MELAS mutations in tRNALeu gene (83% and 63% decrease) [8].
Interestingly, signiﬁcant differences were observed between the ef-
fects of two NARPmutations located in the same nucleotide of ATPase
subunit 6 gene: T8993C and T8993G mutations (22% and 95% de-
crease in ATP synthesis, respectively). This phenomenon was con-
ﬁrmed also in lymphocytes from patients carrying such mutations
at high heteroplasmy level (above 90%) — T8993G mutation led to
about 60–70% drop in the ATP synthesis rate, while T8993C mutation
had only slight effect [9]. This conﬁrms the key importance of this
locus for ATP synthase activity.
The degree of impairment depends also on the heteroplasmy level.
In cells from NARP patients carrying the same mutation, strong corre-
lation was found between the mutation load and the decrease in mi-
tochondrial ATP synthase activity [7,13]. Interestingly, the severity of
the bioenergetic impairment resulting from mtDNA mutations can
also be affected by polymorphisms in other mtDNA genes. This was
shown in cybrid cells with the same nuclear background and the
same homoplasmic mtDNA mutation in ATP synthase subunit 6,
where the level of the ATP synthesis impairment strongly varied (be-
tween 20% and 75% loss of activity) [10].Many studies fail to observe differences in intracellular ATP levels
between wild-type cells and cells with mutated mtDNA, despite
clearly defective mitochondrial ATP synthesis machinery [6,14,15].
Lower ATP synthesis in the mitochondria does not have to be fol-
lowed by decreased cytosolic ATP levels. Studies on cybrids with
NARP or MELAS mutations revealed a decrease in intramitochondrial
ATP levels in cells with mtDNA mutations, without affecting cytosolic
ATP levels if the cells were cultured in the presence of glucose [16].
This is because under resting conditions the energetic needs of the cell
can often be satisﬁed with glycolysis. Indeed, in cells with mutated
mtDNA the upregulation of glycolysis is usually observed, resulting in
high lactate production levels [16,17]. The compensatory role of glyco-
lytic stimulation is evidenced by inverse correlation between lactate
synthesis and respiratory activity reﬂecting ATP synthesis efﬁciency
[8]. Nevertheless, under conditions of increased energetic demands or
low glucose accessibility, glycolysis is not sufﬁcient to satisfy the ener-
getic needs of the cell and ATP depletion usually occurs in respiratory-
impaired cells [6,16,17]. Moreover, studies performed on myoblasts
(which are the cells with high energy demand) carrying MELAS muta-
tions demonstrated not only decrease of ATP level but also general de-
pletion of the intracellular adenine nucleotides pool [18]. The
assumption that loss of efﬁcient mitochondrial ATP synthesis is a
disease-causing factor is supported by the following observation in pa-
tientswithNARPmutation present at different heteroplasmy levels: the
severity of the clinical symptoms correlated with the degree of loss of
the ATP synthase activity [7].
Apart from being the driving force for mitochondrial ATP synthe-
sis, mitochondrial membrane potential is crucial also for protein im-
port into the mitochondria, respiratory substrates uptake or for ion
transport across the inner mitochondrial membrane. Thus, mainte-
nance ofΔΨ is extremely important for proper functioning of mitochon-
dria. ΔΨ is built up due to proton extrusion from the mitochondrial
matrix mediated by the respiratory chain and is consumed mainly by
ATP synthesis. An obvious consequence of themutations in genes coding
for the respiratory chain proteins is decreasedmitochondrial membrane
potential, while ATP synthase dysfunction shall be accompanied by an
increase inΔΨ. Many experimental data conﬁrm such tendency, demon-
strating low ΔΨ levels in cells with mtDNAmutations in genes for respi-
ratory chain complexes [19], while mutations in genes for the ATP
synthase subunits usually result in elevated mitochondrial membrane
potential [9,13]. In addition, Sgarbi et al. have found a clear correlation
between increased ΔΨ and loss of ATP synthase activity in lymphocytes
from patients with NARP mutation at various heteroplasmy levels [13].
Mutations in tRNA genes impair the activities of both: ATP synthase
and respiratory chain complexes. In that case usually a clear decrease
of theΔΨ is observed, due to strongly decreased efﬁciency of respiratory
chain-mediated proton extrusion from the matrix [6,17]. On the other
hand, some investigators fail to observe changes in ΔΨ, despite a clear
genetic and enzymatic defect of the respiratory chain or ATP synthase;
sometimes even the opposite effect is detected (e.g. elevated ΔΨ in
cellswith respiratory dysfunction) [20,21]. Thismay reﬂect the existence
of compensatory mechanisms maintaining appropriate polarization of
mitochondrial inner membrane despite the respiratory chain defect
[1,21].
Even under conditions of strongly dysfunctional respiratory chain
a limited but signiﬁcant value of the proton gradient across the inner
mitochondrial membrane is maintained, which allows to support the
ΔΨ-dependent processes, such as protein import, transport of ions
and metabolites across the inner mitochondrial membrane [22]. In
cells with severely impaired respiratory chain function, ΔΨ is created
mainly due to reversed action of ATP synthase and adenine nucleo-
tides transporter (ANT). ATP hydrolysis and production of ADP3−
provides substrate for the electrogenic exchange of this nucleotide
and ATP4− generated glycolytically in the cytosol [5]. Therefore in
cells with mtDNA mutations mitochondrial depolarization can be ob-
served upon inhibition of ATP synthase or ANT, while in unaffected
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tioned, that ANT activity reversal requires stronger decrease in ΔΨ
than needed for reversal of ATP synthase activity [23]. The potential
to generate ΔΨ despite dysfunctional respiratory chain was shown
in cybrid cell lines derived from embryonic stem cells, differentiated
into neuronal or glial cells [21]. In cells with a mutation in respiratory
complex I ND5 and ND6 subunits, accompanied by strong impairment
of respiratory chain efﬁciency (about 90% decrease in complex I activ-
ity), ΔΨ appeared to be even higher than in control cells. Moreover,
the source of elevated mitochondrial membrane potential seemed
to be different in stem cells than in differentiated neurons, since
only in neurons ΔΨ was dissipated upon ATP synthase inhibition.
Contribution of different mechanisms to ΔΨ formation in respirato-
ry deﬁcient cells was quantiﬁed in rho0 cells derived from osteosarco-
ma 143B cell line [5]. In these cells around 13% of ATP derived from
glycolysiswas used formaintenance ofΔΨ, and ATPhydrolysis together
with ADP3−/ATP4− exchange allowed to keep ΔΨ at the level of about
70 mV (compared to ca. 130 mV in wild-type cells). Later studies have
shown that under physiological circumstances mitochondrial ATP
synthase working in a reversed mode will consume mostly intramito-
chondrially generated ATP [23]. This is in agreement with moderate
consumption of cytosolic ATP for ΔΨ maintenance in Rho0 cells [5].
Other investigations, on HeLa Rho0 cells revealed the additive nature
of the effects of mitochondrial ATP synthase and ANT inhibitors on
ΔΨ and on cell viability [24]. This demonstrates that reversal of ATP
synthase and adenine nucleotide translocase activities are partially in-
dependent mechanisms of ΔΨ formation in mitoDNA-defective cells.
3. Calcium metabolism in cells with mtDNA point mutations
The potential involvement of mitochondria in cellular calciumme-
tabolismwas recognized 50 years ago [25,26]. After decades of doubts
and debates, this involvement is now well documented and wildly
accepted.
On the inner mitochondrial membrane there is a calcium unipor-
ter transport system, responsible for Ca2+ uptake into the mitochon-
drial matrix. Its molecular nature was very recently described [27].
This highly efﬁcient, although relatively low afﬁnity (Kd 10 μM) calci-
um transporter, catalizes the uptake of Ca2+ and is driven by ΔΨ.
When activated due to rising local calcium concentrations it increases
calcium concentration in the mitochondrial matrix, followed by acti-
vation of key mitochondrial dehydrogenases and consequently in-
creased oxidative phosphorylation capacity [28].
The transient activity of the uniporter also modulates speciﬁc cellu-
lar functions through modulation of the spatio-temporal dynamics of
calcium signals in the cytosol. Excess Ca2+ uptake by the mitochondria
can cause a bioenergetic catastrophe, opening of the permeability tran-
sition pore, release of cytochrome c and cellular death by apoptosis or
necrosis. Therefore, abnormal Ca2+homeostasis is linked tomanypath-
ogenic conditions, mitochondrial diseases included.
Even subtle deﬁcits in the electron transfer chain, caused by ge-
netic mutations, affect ΔΨ and thus might inﬂuence Ca2+ homeosta-
sis. Abnormal calcium signals inﬂuence multiple signal cascades
within the cell.
Abnormal calcium homeostasis has been reported in a variety of
non-neuronal cell lines with oxidative phosphorylation defects and
diminished ΔΨ. In ﬁbroblasts derived from MELAS patients, the
basal cytosolic Ca2+ level was increased [14]. In osteosarcoma
MELAS cybrid cells intramitochondrial calcium homeostasis was also
disturbed [15]. In cybrid cells with MERRF syndrome derangement
of mitochondrial calcium homeostasis was found [29]. In NARP
cybrids (with ΔΨ increased or the same as in control cells), cytosolic
and mitochondrial Ca2+ homeostasis was unaffected, and these cells
could accumulate Ca2+ as well as WT cells [29]. In SH-SY5Y neuro-
blastoma Rho0 cells (lacking mtDNA) with drastically reduced ΔΨ,
the basal cytosolic Ca2+ level was reduced [30], whereas in Rho0osteosarcoma cells it was higher than in control cells [31]. Overall,
this means that even small modiﬁcation of ΔΨ in cells with defective
mitochondria affects mitochondrial Ca2+ uptake: when ΔΨ is low-
ered usually Ca2+ uptake is diminished, in the case of ΔΨ enhance-
ment Ca2+ uptake can be upregulated. There are, however, cellular
mechanisms compensating for abnormal respiratory chain activity.
In neuronal cells the role of mitochondria in calcium homeostasis
is somewhat different. Calcium ions are involved in a number of spe-
ciﬁc cellular processes such as transmitter release and action poten-
tial conduction. It has been suggested that defective oxidative
phosphorylation results in ATP deﬁciency, causing persistently ele-
vated level of cytoplasmic Ca2+ and promoting cell death via Ca2+
overload [32].
In patients with mitochondrial diseases, neuronal dysfunction
and neurodegeneration are the most prominent and disabling features.
Ca2+ enters the cytosol mostly from the extracellular space through
voltage-gated Ca2+ channels. Amodel of mature neurons (differentiated
cybrids derived from embryonic stem cells) showed a conventional,
transient Ca2+ response to activation by glutamate [33]. Cells with
mtDNA mutation had a normal baseline response to glutamate, but
after repeated stimulation showed progressive deﬁcit in Ca2+ transients.
In non-neuronal cells (in electrically non-excitable cells), the most
dynamic calcium pool corresponds to the endoplasmic reticulum and
in Ca2+ homeostasis store operated Ca2+ channels play a key role
[34]. Because store operated Ca2+ channels are regulated by mito-
chondria as well [35], in pH dependent way [36], their dysfunctions
may affect neuronal and non–neuronal cells differently. Mutations
in mtDNA can reduce mitochondrial Ca2+ inﬂux, but do not inﬂuence
the calcium content of mitochondria in NARP cybrid cells [29]. In os-
teosarcoma NARP and even Rho0 cells store-operated calcium inﬂux
was independent of mitochondrial energy status. Only slower Ca2+
inﬂux rates were observed in these cell lines in comparison to paren-
tal cells [20].4. ROS production and the antioxidant defence system in cells
with mtDNA point mutations
Under physiological conditions mitochondria are known to pro-
duce a basal level of ROS as a result of imperfections in the respiratory
chain (electron leakage) [37]. Elevated ROS generation by mitochon-
drial respiratory chain occurs when mitochondria are hyperpolarized
and the components of the respiratory chain are highly reduced or in
the case of some dysfunction of the individual respiratory chain sub-
units. Similarly, in some cases the defects in the mitochondrial ATP
synthase may result in mitochondrial hyperpolarization and higher
ROS production because the protonomotive force is not used for the
ATP synthesis. To defend against ROS, cells posses defense systems
which help to counteract the negative effects of ROS and protect
cells from the consequences of the oxidative stress. The system con-
tains the number of antioxidant enzymes e.g. superoxide dysmutases
(SOD1 and SOD2), catalase, glutathione peroxidase (GPx) and gluta-
thione reductase (GR) [38].
Dependences between dysfunction of the respiratory chain
(caused by mutations in mtDNA), ROS production and adaptive re-
sponse of the antioxidant defense system are described in numerous
publications. Lack of the mitochondrial respiratory chain activity in
Rho0 cell lines was accompanied by diminished ROS production and
reduced antioxidant defence efﬁciency [38]. Moreover, detailed studies
on the sites of intracellular ROS generation indicated that in osteosarco-
ma Rho0 cells, ROS are mainly produced extramitochondrially. It has
been well demonstrated that this defect results in a decrease of glutathi-
one reductase activitywhich in consequence shifts the glutathione redox
to the oxidized state. Moreover, the decrease of both SOD1 and SOD2
gene expression as well as protein levels in rhabdomyosarcoma and os-
teosarcoma Rho0 cell lines has been observed [38].
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particular complex of the respiratory chain or ATP synthase is modu-
lated due to mtDNA point mutations. This could be compared to the
treatment of mitochondria by the respiratory chain inhibitors such
as rotenone, antimycin or oligomycin. Such point dysfunction of the
respiratory chain results in increased mitochondrial (mostly superox-
ide anion, O2•−) ROS generation. Pioneering studies concerning this
issue were performed on cell lines derived from patients with mito-
chondrial disease. It was demonstrated, that the activity of the respi-
ratory chain complexes (I and IV) in cells harbouring the A3243G
mutation (in most cases responsible for MELAS syndrome) was sig-
niﬁcantly decreased [39–41]. Subsequent studies showed that in-
creased total superoxide dismutase and catalase activities could be
considered an adaptive response to increased ROS production in
cells carrying A3243G mutation in tRNALeu gene [18]. Lee at al. dem-
onstrated that up-regulation of SOD2 in ﬁbroblasts carrying MERRF
mutations is related to the activation of protein kinase C delta
(PKCδ) signalling cascades [42,43].
Increased ROS production was also found in ﬁbroblasts from pa-
tients with diagnosed MERRF syndrome harbouring A8344G muta-
tion in tRNALeu gene. Moreover, mitochondrial O2•− production in
cells with point mutations in mtDNA encoding complex III of the re-
spiratory chain was also elevated [44]. Upregulation of ROS produc-
tion and simultaneous down-regulation of antioxidant enzymes
level by the PKCbeta-dependent phosphorylation of p66Shc upon cel-
lular response to the oxidative stress were observed in skin ﬁbro-
blasts of children harbouring different mitochondrial disorders [45].
Progress in the studies of mitochondrial disorders accelerated
with the use of cybrid cell lines. Using this experimental model —
two cybrid cell lines with mutated mitochondrial tRNA genes
(A3243G in tRNA LeuUUR and A8344G in tRNA Lys) and one carrying
mutation in subunit I of cytochrome c oxidase (the stop-codon muta-
tion G6930A), Vives-Bauza et al. studied dependences between anti-
oxidant defence system and oxidative stress with mitochondrial
origin [46]. They have found signiﬁcant increase in ROS production
in both MERRF and MELAS tRNA mutant cybrids accompanied by in-
creased SOD1, SOD2 and catalase activities. Interestingly, no expected
cellular symptoms of the oxidative stress (proteins carbonylation or
lipids peroxidation) have been observed in these cells. It has been con-
cluded that the lack of oxidative stress is a direct effect of the antioxidant
enzymes upregulation. In contrast to themt tRNAMERF andMELASmu-
tations, the cytochrome c oxidase mutant human osteosarcoma cybrid
cells (carrying the stop-codon mutation G6930A in the COXI gene) had
similar ROS production rate and levels of antioxidant enzymes to isogen-
ic control cells. This indicates that themutations described above, affect-
ing complex IV do not increase ROS production [46]. More recently Wu
et al. presented different results for MERRF patients with A8344Gmuta-
tion in tRNALeu gene. In cells from patients with diagnosed MERRF syn-
drome only SOD2 (mRNA, protein, and enzyme activity levels) has been
found upregulated. The other antioxidant enzymes, such as SOD1, GPx
and catalase did not show signiﬁcant changes [47]. Similarly, in human
osteosarcoma NARP cybrid cells with 98% of T8993G mutation load, de-
fect in the mitochondrial ATP synthase is accompanied by changes in
ROS generation and antioxidant defence system. [48]. In ﬁbroblasts de-
rived from NARP patients direct correlation between mtDNA mutation,
oxidative stress and oxidative damage were observed [49].
Studies performed with the use of three osteosarcoma cybrid cell
lines carrying homoplasmic point mutations in ND4 (11778), ND1
(3460) and ND6 (14484) mtDNA genes encoding complex I subunits
of the respiratory chain (associated with LHON) showed enhanced
mitochondrial ROS production [50]. The increased mitochondrial su-
peroxide anion has been observed also in another cybrid model, neu-
ronal (NT2) cybrid cell line carrying the ND4 (11778) and ND1
(3460) LHON mutations [51]. In LHON-affected osteosarcoma cybrids
11778/ND4, 3460/ND1 and 14484/ND6 the activities of SOD1, SOD2
and glutathione reductase activity were decreased [52].In the above described experimental models (cybrid cells, ﬁbro-
blasts derived from patients), the increased ROS production seemed
to be directly related to mtDNA damage. This view has been chal-
lenged by the studies on mtDNA mutator mice (homozygous knock-
in mice that express a proof-reading-deﬁcient version of PolgA, the
nucleus-encoded catalytic subunit of mtDNA polymerase). Such mito-
chondrial DNA polymerase defect leads to strongly increased number
of mtDNA mutations. However, in this model no increased ROS pro-
duction (H2O2), protein carbonylation, lipid peroxidation and oxida-
tive damage of nucleic acids were observed [53,54]. Unchanged
expression level of antioxidant enzymes in mtDNA-mutator mice
seemed to indicate that the increased level of mtDNA mutations is
not associated with increased ROS production [54]. In the light of con-
tradictory results from various experimental models, the direct rela-
tion between mtDNA mutations and elevated mitochondrial ROS
production is still an opened question.
5. Mitochondrial morphology and dynamics in cells with mtDNA
point mutations
Mitochondrial morphology, dynamics and organization play an im-
portant role in living cells. It is well established that mitochondria are
highly motile and remarkably plastic organelles. Two events, fusion
and ﬁssion, that control mitochondrial morphology and mitochondrial
network, can contribute to the repair of defective mitochondria, their
proper segregation into daughter cells during cell division, the efﬁciency
of oxidative phosphorylation, intramitochondrial calcium signal propa-
gation, mtDNA integrity and cell death [55].
Speciﬁc proteins of the dynamin family GTPases are engaged in
mitochondrial ﬁssion: dynamin-related protein 1 (DRP1) and Fis1.
Drp 1 is located predominantly in the cytosol and the pool of this pro-
tein translocates to mitochondrial tubules where it interacts with Fis1
protein forming ﬁssion sites. An inhibition of Drp1 function leads to
the formation of highly fused and tubular mitochondrial network
[56]. Fission of mitochondria plays the main role in cell survival and
cell death. For example, mitochondrial inheritance depends on mito-
chondrial ﬁssion during cytokinesis, and mitochondrial division is im-
portant for formation of synapses and dendritic spines in neurons.
Fission machinery also participates in the process of apoptosis by in-
ducing fragmentation of the mitochondrial network.
Fusion is controlled by mitofusin-1, mitofusin-2 and OPA 1. Mito-
chondrial fusion is required for maintenance of mitochondrial DNA,
and its inhibition reduces the activity of the respiratory chain and mi-
tochondrial metabolism [57].
Other important and essential aspects of mitochondrial dynamics
are motility and positioning of mitochondria within the cell that in-
volve many motor and cytoskeletal proteins. In mammalian cells, mi-
tochondria travel along microtubules by association with dyneins and
kinesins [58]. The primary functions of mitochondrial positioning at
local sites are ATP provision and calcium transient buffering. Defects
in mitochondrial distribution manifest themselves in highly polarized
and metabolically active cells. Since the proper transport and intracel-
lular distribution of mitochondria are crucial for normal physiology of
such cells, disruptions of mitochondrial dynamics are often implicated
in the pathogenesis of various neurological diseases, cellular senescence
and muscle atrophy [59].
In humans,mutations in genes regulatingmitochondrialmorphology
are linked to neurodegenerative diseases such as autosomal dominant
optic atrophy — ADOA (mutation in Opa1 gene), a common form of
inherited childhood blindness, and Charcot–Marie–Tooth disease type
2A (mutation in mitofusin-2 gene), a neurodegenerative disorder clini-
cally characterized by the gradual degeneration of peripheral neurons.
It is well established that changes in mitochondrial metabolism af-
fect mitochondrial shape and organization within the cell. Pharmaco-
logical inhibition of respiratory chain complexes alters organization of
the mitochondrial network, mitochondrial membrane potential and
Fig. 1. Mitochondrial factors — typical consequences of mtDNA point mutations. These changes can be modiﬁed depending on a cell type (oxidative vs. glycolytic, cells with intensive
metabolism vs. slow metabolism), genetic background and level of heteroplasmy.
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(e.g. by cyanide) ﬁrst causes shrinkage of mitochondria and then mi-
tochondrial fragmentation and swelling. Increased ROS production
also triggers dynamic changes in the morphology of the organelles
by mitochondrial fragmentation [62]. An intact mitochondrial mem-
brane potential was found to be crucial for mitochondrial fusion and
shape changes as well [63]. Protonophores dissipating inner mito-
chondrial membrane potential completely inhibit fusion and result
in rapid, but reversible fragmentation of mitochondria whereas niger-
icin which increases mitochondrial membrane potential, stimulates
mitochondrial contacts [64].
Studies of mitochondrial organization in cells with mtDNA muta-
tions show some abnormalities of mitochondrial structure and
shape. These observations were made with respect to skin ﬁbroblast
cells with complex I dysfunction caused by mutations in nuclear
genes encoding complex I subunits and cells with complex I dysfunc-
tion induced by pharmacological agents. Koopman et al. [65,66]
showed that mitochondria were fragmented and/or less branched.
Studies of skin ﬁbroblasts from patients with mitochondrial complex
I deﬁciency and healthy ﬁbroblasts during rotenone or antimycin A
treatment showed an increased number of swollen, ﬁlamentous
mitochondria and nodal ﬁlament [67].
Investigation of other cells with complex I dysfunction caused by
mtDNA point mutation, and LHONmuscle samples (obtained post mor-
tem) revealed abnormalities and disruption of mitochondrial network
in some muscle ﬁbres. Many mitochondria had lost their inner cristae,
formed a “ghost proﬁle” or obtained the cristae shape deﬁned as
“onion ring” as well as exhibited an increased volume [68]. Ultrastruc-
ture of brain tissue obtained from patients with Leigh disease (frag-
ments of spongy degenerated white matter) also showed abnormal
enlarged mitochondria with aberrant conﬁgurations of cristae, some-
times with few of them situated in the centre [69]. In MELAS cerebral
tissue biopsy electron microscopy revealed abnormal, irregular and
concentric cristae structure in the mitochondria [70]. Moreover, in a
liver sample obtained from patients diagnosed with Pearson syndrome,
some mitochondria had few or revealed no cristae at all [71].
The mitochondrial morphology study was also performed on
cybrid MELAS and NARP cells that harbored mtDNA mutations, and
revealed mitochondrial fragmentation [20,72]. In MERRF cybrids, it
was found that proteolytic OPA1 processing was accelerated [72].
An increased fragmentation and density of mitochondria was also
shown in proximal nerves and muscles of Drosophilawith mtDNA de-
pletion [73]. Yeast cells lacking the mitochondrial gene encoding the
ATP synthase subunit 6 also exhibited deformed mitochondria with
condensed mitochondrial compartment [74].Apart from diseases caused by mutations in mitochondrial ge-
nome, many studies suggested a possible role of mitochondrial
mtDNA mutations in sporadic neurodegenerative diseases such as
stroke, Parkinson's, Huntington's, and Alzheimer's diseases [75].6. Summary
The genetics and pathophysiology of mitochondrial diseases are
slowly unravelled. Some of these diseases are initiated by point muta-
tions in mtDNA. Most of the relevant biochemical studies were carried
out on cell lines derived from patients, usually on ﬁbroblasts or lym-
phocytes. On the cellular level, consequences of mtDNA mutations
(Fig. 1) depend on cell type (cells predominantly oxidative vs. glycolyt-
ic; cells with intensive metabolism vs. slowmetabolism), genetic back-
ground, level of the penetration of a given mutation (heteroplasmy)
and physiological state of cell (resting vs. activated). Thus, results de-
scribing the consequences of mtDNA mutations on cultured cells are
contradictory. However, a clearer picture starts to emerge. Pathogenic
pointmutations inmtDNA disturb the activity ofmtDNA-encoded com-
ponents of the respiratory chain or/and mitochondrial ATP synthase.
Thus, modiﬁcations of mitochondrial membrane potential (ΔΨ) and
the redox state of components of the respiratory chain occur. The
change in these two mitochondrial parameters may lead to lower ATP
level in the cell, abnormalities in cellular calcium metabolism and
changes in mitochondrial ROS production. Moreover, ΔΨ inﬂuences
mitochondrial dynamics.
In a future, more studies are needed to correlate changes of mito-
chondrial factors in cells with mtDNA point mutations with a pheno-
type of a given cell line.Acknowledgements
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